PyrAmes platforms will provide options to continuously monitor blood pressure cNIBP for patients of all ages.
could benefit from BP monitoring but would not receive an arterial line because it is invasive and costly.2
50% of adults are affected by high blood pressure in the US, increasing their mortality rates.3
Raised blood pressure (BP) is responsible for 7.6 million deaths worldwide annually.4
cNIBP has the potential for early detection of conditions within preterm infants and adults.
1. Quan, X.; Liu, J.; Roxlo, T.; Siddharth, S.; Leong, W.; Muir, A.; Cheong, S.-M.; Rao, A. Advances in Non-Invasive Blood Pressure Monitoring. Sensors 2021, 21, 4273. https://doi.org/10.3390/s21134273
2. Haidari, E. S., Lee, H. C., Illuzzi, J. L., Phibbs, C. S., Lin, H., & Xu, X. (2020). Hospital variation in admissions to neonatal intensive care units by diagnosis severity and category. Journal of Perinatology, doi:10.1038/s41372-020-00775-z
PyrAmes has been awarded a Catalyzing Pediatric Innovation (CPI) grant by the West Coast Consortium for Technology & Innovation in Pediatrics (CTIP), centered at Children's Hospital Los Angeles. Including PyrAmes, only five innovators were selected for developing novel devices and technologies for pediatric patients in CTIP’s seventh annual competition. PyrAmes was selected for its novel approach to monitor the blood pressure of critically-ill, yet stabilized, infants who have not yet been treated for hypotension, by extending the use of its non-invasive, wearable Boppli® device. There were ~3.6 million live U.S. births in 2020, with 9% to 13% requiring NICU care (~400,000), including monitoring of vital signs such as blood pressure. CTIP is a pediatric medical device accelerator centered at Children's Hospital Los Angeles (CHLA) and the University of Southern California (USC). CTIP promotes the commercialization and clinical use of pediatric medical device technology. Its goal is to support innovators and encourage development of safe, effective medical devices designed specifically for pediatric patients.
CUPERTINO, CA and ARLINGTON, VA — PyrAmes Inc. has received an investment from March of Dimes, the leading organization fighting for the health of moms and babies, to support development and commercialization of its wearable technology to noninvasively monitor blood pressure, particularly for new mothers and their babies. PyrAmes' goal is to develop more convenient, clinically-accurate, blood pressure monitoring for all patients, including both mothers and babies in order to support enhancing their health before and after childbirth. PyrAmes’ Boppli™ device for critically-ill infants received Breakthrough Device Designation from the US Food & Drug Administration (FDA). (more…)
2020 FDA Breakthrough Device Designation
Founding Member of CDC National Hypertension Control Roundtable
2020 SWPDC Pediatric Device Award, Member of SWPDC
2019 MedTech Innovator Accelerator & 2020 NCC-PDI MedTech Innovator Pediatric Accelerator
Exponential Medicine 2019 One to Watch Award